BURLINGTON, Mass., Oct. 9, 2017 /PRNewswire/ -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) will hold a conference call today, Monday, October 9, 2017, at 8:00 a.m. ET to discuss the recent U.S. Food and Drug Administration (FDA) approval of ZILRETTA(TM) (triamcinolone acetonide extended-release injectable suspension). ZILRETTA, the first and only extended-release, intra-articular injection for osteoarthritis knee pain, received FDA approval on Friday, October 6. ZILRETTA is a non-opioid medicine that employs Flexion's proprietary microsphere technology to provide proven pain relief over 12 weeks.

View the company's multimedia news release announcing the approval:
https://www.multivu.com/players/English/8186951-flexion-therapeutics-zilretta-fda-approval/

Conference Call Details
 Monday, October 9, 2017, at 8:00 a.m. ET. The dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID # 92539488. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website, and a replay will be available online after the call.

Flexion expects ZILRETTA will be available in the U.S. by the end of October. For more information, visit www.ZILRETTA.com or call 1-844-FLEXION.

Indication and Important Safety Information

Indication: ZILRETTA(TM) (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: ZILRETTA is not intended for repeat administration.*

Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.

Warnings and Precautions


    --  Intra-articular Use Only: ZILRETTA has not been evaluated and should not
        be administered by epidural, intrathecal, intravenous, intraocular,
        intramuscular, intradermal or subcutaneous routes. Serious events have
        been reported with epidural and intrathecal administration of
        corticosteroids and none are approved for this use. ZILRETTA should not
        be considered safe for epidural or intrathecal administration.
    --  Hypersensitivity Reactions: Rare instances of anaphylaxis, including
        serious cases, have occurred in patients with hypersensitivity to
        corticosteroids.
    --  Joint Infection and Damage: A marked increase in pain accompanied by
        local swelling, restriction of joint motion, fever and malaise are
        suggestive of septic arthritis. Examine joint fluid to exclude a septic
        process. If diagnosis is confirmed, institute appropriate antimicrobial
        therapy. Avoid injecting corticosteroids into a previously infected or
        unstable joint. Intra-articular administration may result in damage to
        joint tissues.
    --  Increased Risk of Infections: Infection with any pathogen in any
        location of the body may be associated with corticosteroid use.
        Corticosteroids may increase the susceptibility to new infection and
        decrease resistance and the ability to localize infection.
    --  Alterations in Endocrine Function: Corticosteroids can produce
        reversible hypothalamic-pituitary-adrenal axis suppression, with
        potential for adrenal insufficiency after withdrawal of treatment, which
        may persist for months. In situations of stress during that period,
        institute corticosteroid replacement therapy.
    --  Cardiovascular and Renal Effects: Corticosteroids can cause blood
        pressure elevation, salt and water retention and increased potassium
        excretion. Monitor patients with congestive heart failure, hypertension
        and renal insufficiency for edema, weight gain and electrolyte
        imbalance. Dietary salt restriction and potassium supplementation may be
        needed.
    --  Increased Intraocular Pressure: Corticosteroid use may be associated
        with increased intraocular pressure. Monitor patients with elevated
        intraocular pressure for potential treatment adjustment.
    --  Gastrointestinal Perforation: Corticosteroid administration may increase
        risk of gastrointestinal perforation in patients with certain GI
        disorders and fresh intestinal anastomoses. Avoid corticosteroids in
        these patients.
    --  Alterations in Bone Density: Corticosteroids decrease bone formation and
        increase bone resorption. Special consideration should be given to
        patients with or at increased risk of osteoporosis prior to treatment.
    --  Behavior and Mood Disturbances: Corticosteroids may cause adverse
        psychiatric reactions. Prior to treatment, special consideration should
        be given to patients with previous or current emotional instability or
        psychiatric illness. Advise patients to immediately report any behavior
        or mood disturbances.

Adverse Reactions: The most commonly reported adverse reactions (incidence >=1%) in clinical studies included sinusitis, cough and contusions.

Please see the full Prescribing Information at www.ZILRETTAlabel.com.

* The efficacy and safety of repeat administration of ZILRETTA have not been evaluated.

About ZILRETTA
 ZILRETTA is the first and only FDA-approved extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide -- a commonly administered, short-acting corticosteroid -- with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief over 12 weeks.

About Osteoarthritis (OA) of the Knee
OA, also known as degenerative joint disease, affects more than 30 million Americans and accounts for more than $185 billion in annual expenditures. In 2016, more than 15 million Americans were diagnosed with OA of the knee and the average age of physician-diagnosed knee OA has fallen by 16 years, from 72 in the 1990s to 56 in the 2010s. The prevalence of OA is expected to continue to increase as a result of aging, obesity and sports injuries. Each year, more than 15 million Americans are treated for OA-related knee pain, and approximately five million OA patients receive either an immediate-release corticosteroid or hyaluronic acid intra-articular injection to manage their knee pain.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq: FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the Boston Business Journal's 2017 Best Places to Work.

Forward-Looking Statements
 Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the future of Flexion; timing for the expected commercial availability of ZILRETTA; our plans to commercialize ZILRETTA and its market potential; expected increases in the rate of individuals with OA of the knee; and the potential therapeutic and other benefits of ZILRETTA, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with the process of launching a new pharmaceutical product in the United States; the risk that we may not be able to maintain and enforce our intellectual property, including intellectual property related to ZILRETTA; competition from alternative therapies; the risk that we may not be able to successfully hire, train and maintain an effective sales force to commercialize ZILRETTA; the risk that ZILRETTA may not be successfully commercialized, including as a result of limitations in ZILRETTA's label and package insert information; risks regarding our ability to obtain adequate reimbursement from payors for ZILRETTA; risks related to the manufacture and distribution of ZILRETTA, including our reliance on sole sources of supply and distribution; risks related to key employees, markets, economic conditions, health care reform, prices and reimbursement rates; and other risks and uncertainties described in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Corporate Contact:
 Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com

View original content:http://www.prnewswire.com/news-releases/flexion-therapeutics-to-hold-conference-call-at-800-am-et-to-discuss-recent-fda-approval-of-zilretta-triamcinolone-acetonide-extended-release-injectable-suspension-300532993.html

SOURCE Flexion Therapeutics